BCM
LENZ

Bridgeway Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Bridgeway Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-21,920
Closed -$379K – 1326
2024
Q2 		$379K Hold
21,920
– – 0.01% 922
2024
Q1 		$489K Sell
21,920
-2,759
-11% -$57.4K 0.01% 938
2023
Q4 		$453K Hold
24,679
– – 0.01% 965
2023
Q3 		$428K Buy
24,679
+6,058
+33% +$105K 0.01% 924
2023
Q2 		$339K Sell
18,621
-208
-1% -$4.16K 0.01% 1015
2023
Q1 		$323K Buy
18,829
+186
+1% +$3.01K 0.01% 990
2022
Q4 		$433K Buy
18,643
+2,429
+15% +$56.3K 0.01% 914
2022
Q3 		$360K Buy
+16,214
New +$386K 0.01% 980

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bridgeway Capital Management's LENZ Position: Q3 2024 in Review

Bridgeway Capital Management sold out of LENZ Therapeutics (LENZ) in Q3 2024, closing a stake of 21,920 shares — an estimated $379K sold.

Bridgeway Capital Management first reported a position in LENZ in Q3 2022 and held it in 8 quarters. The position peaked at $489K in Q1 2024. 78 funds tracked by Wall St. Rank hold LENZ as of Q3 2024.

  • Bridgeway Capital Management reported no remaining LENZ Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bridgeway Capital Management sold 21,920 LENZ Therapeutics shares in Q3 2024, an estimated $379K.
  • Bridgeway Capital Management first reported a position in LENZ Therapeutics in Q3 2022 and held it in 8 quarters.
  • Bridgeway Capital Management's LENZ Therapeutics position peaked at $489K in Q1 2024.
  • 78 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2024.

Based on Bridgeway Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.